Skip to content
Our Focus
Pterygium Overview
Pterygium Therapy
Pinguecula Overview
Pinguecula Therapy
Technology
Multi-Kinase Inhibitors (MKIs)
Semi-Fluorinated Alkanes+ (SFA+)
Pipeline
CBT-001
CBT-004
CBT-009
CBT-199
Active Clinical Trials
About
Overview
Management
Scientific Advisory Board
Our Partners
News
InvestorRelations
Corporate Presentation Deck
How to Buy Cloudbreak Pharma Stock
Announcements & Presentations
Financial Reports
Listing Documents
Corporate Governance
Arrangement of Electronic Dissemination of Corporate Communications
Stock Chart
Contact
English
繁體中文
简体中文
Our Focus
Pterygium Overview
Pterygium Therapy
Pinguecula Overview
Pinguecula Therapy
Technology
Multi-Kinase Inhibitors (MKIs)
Semi-Fluorinated Alkanes+ (SFA+)
Pipeline
CBT-001
CBT-004
CBT-009
CBT-199
Active Clinical Trials
About
Overview
Management
Scientific Advisory Board
Our Partners
News
InvestorRelations
Corporate Presentation Deck
How to Buy Cloudbreak Pharma Stock
Announcements & Presentations
Financial Reports
Listing Documents
Corporate Governance
Arrangement of Electronic Dissemination of Corporate Communications
Stock Chart
Contact
English
繁體中文
简体中文
An Innovative Biotech with a Robust R&D Engine Driving the Development of First-in-Class and Best-in-Class Ophthalmic Drugs
document.addEventListener('DOMContentLoaded', function() { document.querySelectorAll('video').forEach(function(video) { video.setAttribute('playsinline', ''); video.setAttribute('muted', ''); video.play().catch(function(){}); }); });